Your session is about to expire
← Back to Search
Small Molecule
Branaplam for Huntington Disease (VIBRANT-HD Trial)
Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to approximately 2 years
Awards & highlights
VIBRANT-HD Trial Summary
This trial is testing a new drug to see if it can lower the amount of a harmful protein in people with Huntington's Disease.
Eligible Conditions
- Huntington Disease
VIBRANT-HD Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline up to approximately 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to approximately 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of treatment emergent adverse events and serious adverse events
Reduction (%) of mHTT protein in cerebrospinal fluid (CSF)
Secondary outcome measures
Area under the curve (AUC) of UFB112 in plasma
Area under the curve (AUC) of branaplam in plasma
Change from baseline in Ventricular Volume, Caudate Volume and Total Brain Volume
+16 moreVIBRANT-HD Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment Arm C or X or YExperimental Treatment1 Intervention
(C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly
Group II: Treatment Arm BExperimental Treatment1 Intervention
Branaplam 112 mg oral solution once weekly
Group III: Treatment Arm AExperimental Treatment1 Intervention
Branaplam 56 mg oral solution once weekly
Group IV: PlaceboPlacebo Group1 Intervention
Matching placebo oral solution once weekly
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Branaplam
2021
Completed Phase 2
~30
Find a Location
Who is running the clinical trial?
Novartis PharmaceuticalsLead Sponsor
2,866 Previous Clinical Trials
4,199,300 Total Patients Enrolled
1 Trials studying Huntington Disease
44 Patients Enrolled for Huntington Disease
Media Library
Research Study Groups:
This trial has the following groups:- Group 1: Treatment Arm A
- Group 2: Treatment Arm B
- Group 3: Treatment Arm C or X or Y
- Group 4: Placebo
Awards:
This trial has 0 awards, including:Share this study with friends
Copy Link
Messenger